Your browser doesn't support javascript.
Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis.
Alsagaff, Mochamad Yusuf; Mulia, Eka Prasetya Budi; Maghfirah, Irma; Luke, Kevin; Nugraha, David; Rachmi, Dita Aulia; Septianda, Imanita; A'yun, Maya Qurota.
  • Alsagaff MY; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia; Universitas Airlangga Hospital, Surabaya, Indonesia. Electronic address: yusuf_505@fk.unair.ac.id.
  • Mulia EPB; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia.
  • Maghfirah I; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia.
  • Luke K; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
  • Nugraha D; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
  • Rachmi DA; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia.
  • Septianda I; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia.
  • A'yun MQ; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Cardiology and Vascular Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia.
Diabetes Metab Syndr ; 15(5): 102210, 2021.
Article in English | MEDLINE | ID: covidwho-1313054
ABSTRACT

AIMS:

This meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes.

METHODS:

PubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality.

RESULTS:

A total of 119,298 patients from 31 eligible studies were included. Pooled analysis of the random-effect model revealed CCB was not associated with reduced mortality (OR = 1.21 [95%CI 0.98-1.49], p = 0.08). Interestingly, subgroup analysis in hypertensive patients revealed significantly reduced mortality (OR = 0.69 [95%CI 0.52-0.91], p = 0.009).

CONCLUSION:

CCB usage was not associated with the outcome of COVID-19. However, CCB was associated with a decreased mortality rate in hypertensive COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Calcium Channel Blockers / COVID-19 Type of study: Diagnostic study / Prognostic study / Randomized controlled trials / Reviews Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Diabetes Metab Syndr Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Calcium Channel Blockers / COVID-19 Type of study: Diagnostic study / Prognostic study / Randomized controlled trials / Reviews Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Diabetes Metab Syndr Year: 2021 Document Type: Article